The Mechanism of Adeno-associated Virus (AAV) Gene Therapy

Jiayin Huang

doi:10.54097/ma9x1289

Authors

Jiayin Huang

DOI:

https://doi.org/10.54097/ma9x1289

Keywords:

AAV vectors, gene therapy, mechanism, serotype.

Abstract

Adeno-associated Virus (AAV) vector has become an important tool for vivo gene therapy due to its high specificity, low immunogenicity and long-term expressibility. There are multiple novel pharmaceuticals utilizing recombinant AAV vectors to treat genetic defect disease or disease related to gene expression disorder that are undergoing clinical trials. In this review, the basic biological features of AAV viruses are introduced, including their structure, classification, and interactions with hosts. This paper aims to elucidate the commonalities and differences among several AAV viruses used in clinical treatment by analyzing existing literature. The relevant genes for transduction of various types of AAV viruses are specifically analyzed in this article. By elaborating the process and mechanism of AAV virus transduction-related gene expression, this paper also attempts to summarize the current achievements of AAV therapy and explain the limitations still existing. It is hoped to contribute to the development and progress of AAV therapy in the future.

Downloads

Download data is not yet available.

References

[1] Kuzmin DA, Shutova MV, Johnston NR, Smith OP, Fedorin VV, Kukushkin YS, van der Loo JCM, Johnstone EC. The clinical landscape for AAV gene therapies. Nat Rev Drug Discov. 2021 Mar; 20 (3): 173-174. doi: 10.1038/d41573-021-00017-7. PMID: 33495615.

[2] Robert W. Atchison, Bruce C. Casto, William McD. Hammon., Adenovirus-Associated Defective Virus Particles.Science149, 754-756 (1965). DOI: 10.1126/science.149.3685.754

[3] Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019 May; 18 (5): 358-378. doi: 10.1038/s41573-019-0012-9. PMID: 30710128; PMCID: PMC6927556.

[4] Au HKE, Isalan M, Mielcarek M. Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings. Front Med (Lausanne). 2022 Feb 9; 8: 809118. doi: 10.3389/fmed.2021.809118. PMID: 35223884; PMCID: PMC8864161.

[5] Ronzitti G, Gross DA, Mingozzi F. Human Immune Responses to Adeno-Associated Virus (AAV) Vectors. Front Immunol. 2020 Apr 17; 11: 670. doi: 10.3389/fimmu.2020.00670. PMID: 32362898; PMCID: PMC7181373.

[6] Chen YC, Liu XP, Xiao PH. Adeno-associated virus vector and its application in gene therapy [J]. Journal of Kunming University of Technology (Natural Science Edition), 2024, 49 (03): 188-201. (In Chinese)

[7] Pipe S, Leebeek FWG, Ferreira V, Sawyer EK, Pasi J. Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer. Mol Ther Methods Clin Dev. 2019 Sep 10; 15: 170-178. doi: 10.1016/j.omtm.2019.08.015. PMID: 31660419; PMCID: PMC6807344.

[8] Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther. 2010 Jan; 18 (1): 80-6. doi: 10.1038/mt.2009.255. Epub 2009 Nov 10. PMID: 19904234; PMCID: PMC2839202.

[9] Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol. 1983 Feb; 45 (2): 555-64. doi: 10.1128/JVI.45.2.555-564.1983. PMID: 6300419; PMCID: PMC256449.

[10] Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008 Jun; 16 (6): 1073-80. doi: 10.1038/mt.2008.76. Epub 2008 Apr 15. PMID: 18414476.

[11] Hung SS, Chrysostomou V, Li F, Lim JK, Wang JH, Powell JE, Tu L, Daniszewski M, Lo C, Wong RC, Crowston JG, Pébay A, King AE, Bui BV, Liu GS, Hewitt AW. AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo. Invest Ophthalmol Vis Sci. 2016 Jun 1; 57 (7): 3470-6. doi: 10.1167/iovs.16-19316. PMID: 27367513.

[12] Newman NJ, Carelli V, Taiel M, Yu-Wai-Man P. Visual Outcomes in Leber Hereditary Optic Neuropathy Patients With the m.11778G>A (MTND4) Mitochondrial DNA Mutation. J Neuroophthalmol. 2020 Dec; 40 (4): 547-557. doi: 10.1097/WNO.0000000000001045. PMID: 32969847.

[13] MacLaren RE, Fischer MD, Gow JA, Lam BL, Sankila EK, Girach A, Panda S, Yoon D, Zhao G, Pennesi ME. Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial. Nat Med. 2023 Oct; 29 (10): 2464-2472. doi: 10.1038/s41591-023-02520-3. Epub 2023 Oct 9. PMID: 37814062; PMCID: PMC10579095.

[14] Mitsios A, Dubis AM, Moosajee M. Choroideremia: from genetic and clinical phenotyping to gene therapy and future treatments. Ther Adv Ophthalmol. 2018 Dec 27; 10: 2515841418817490. doi: 10.1177/2515841418817490. PMID: 30627697; PMCID: PMC6311551.

[15] Sharma A, Ghosh A, Hansen ET, Newman JM, Mohan RR. Transduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblasts. Brain Res Bull. 2010 Feb 15; 81 (2-3): 273-8. doi: 10.1016/j.brainresbull.2009.07.005. Epub 2009 Jul 16. PMID: 19616080; PMCID: PMC2814910.

[16] Bantel-Schaal U, zur Hausen H. Characterization of the DNA of a defective human parvovirus isolated from a genital site. Virology. 1984 Apr 15; 134 (1): 52-63. doi: 10.1016/0042-6822(84)90271-x. PMID: 6324476.

[17] Genus: Dependoparvovirus. ICTV. (n.d.). Retrieved April 24, 2022, from https://talk.ictvonline.org/ictv-reports/ictv_online_report/ssdna-viruses/w/parvoviridae/1043/genus-dependoparvovirus.

[18] Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, Symington E, Quon DV, Wang JD, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O'Mahony B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, Yang X, Wong WY, Kim B; GENEr8-1 Trial Group. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022 Mar 17; 386 (11): 1013-1025. doi: 10.1056/NEJMoa2113708. PMID: 35294811.

[19] Mohan RR, Gupta S, Kumar R, Sinha NR, Landreneau J, Sinha PR, Tandon A, Chaurasia SS, Hesemann NP. Tissue-targeted and localized AAV5-DCN and AAV5-PEDF combination gene therapy abrogates corneal fibrosis and concurrent neovascularization in rabbit eyes in vivo. Ocul Surf. 2024 Apr; 32: 13-25. doi: 10.1016/j.jtos.2024.01.001. Epub 2024 Jan 6. PMID: 38191093.

[20] Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002 Sep 3; 99 (18): 11854-9. doi: 10.1073/pnas.182412299. Epub 2002 Aug 21. PMID: 12192090; PMCID: PMC129358.

[21] Sands MS. AAV-mediated liver-directed gene therapy. Methods Mol Biol. 2011; 807: 141-57. doi: 10.1007/978-1-61779-370-7_6. PMID: 22034029; PMCID: PMC4118577.

[22] Pan X, Yue Y, Zhang K, Hakim CH, Kodippili K, McDonald T, Duan D. AAV-8 is more efficient than AAV-9 in transducing neonatal dog heart. Hum Gene Ther Methods. 2015 Apr; 26 (2): 54-61. doi: 10.1089/hgtb.2014.128. Epub 2015 Apr 1. PMID: 25763686; PMCID: PMC4403016.

[23] Lai NC, Gao MH, Giamouridis D, Suarez J, Miyanohara A, Parikh J, Hightower S, Guo T, Dillmann W, Kim YC, Diaz-Juarez J, Hammond HK. Intravenous AAV8 Encoding Urocortin-2 Increases Function of the Failing Heart in Mice. Hum Gene Ther. 2015 Jun; 26 (6): 347-56. doi: [24]10.1089/hum.2014.157. Epub 2015 Apr 9. PMID: 25760560; PMCID: PMC4492611.

[24] Chen PG, Sun Z. AAV Delivery of Endothelin-1 shRNA Attenuates Cold-Induced Hypertension. Hum Gene Ther. 2017 Feb; 28 (2): 190-199. doi: 10.1089/hum.2016.047. Epub 2016 Oct 11. PMID: 27736201; PMCID: PMC5312589.

The Mechanism of Adeno-associated Virus (AAV) Gene Therapy

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

Issue

Section

License

Indexing